Elizabeth Holmes also stepped down from her position as Theranos CEO on Friday, to be replaced by the company's general counsel David Taylor.

The researchers used multiple-reaction monitoring mass spec to create a more sensitive assay to AFP-L3, a protein marker for hepatocellular carcinoma.

The company is planning to submit the drug and a companion diagnostic that can identify patients with FGFR alterations with the FDA in the second half of 2018.

The UK government aims to create six centers specializing in digital pathology, medical imaging or both, working together through a framework agreement.